Patients with breast cancer positive for estrogen receptor (ER) or human epidermal growth factor (GF) receptor type 2 (HER2) initially respond well to anti-estrogen or anti-HER2 therapy, respectively, but inevitably become refractory.[3]. This evidence concerns the gene ERBB2 and breast carcinoma.